Naslov
Risperidone oral solution, therapeutic possibility in treatment of acute and agitated psychotic patients

Autori
Lasić, Davor ; Rubeša, Gordana ; Dodig, Goran ; Katavić, Zdenko ; Glavina, Trpimir ; Žuljan Cvitanović, Marija.

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, ostalo

Izvornik
European Neuropsychopharmacology / - Pariz, 2006, 445-446

Skup
19th European College of Neuropsychopharmacology

Mjesto i datum
Pariz, Francuska, 16.09.2006. - 20.09.2006

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
risperidon; oralna otopina; agitacija; shizofrenija
(risperidone; oral solution; agitation; schizophrenia)

Sažetak
Statement of the study: Efficacy of the risperidone oral solution, as new, effective therapeutic possibility in the treatment of acute and agitated psychotic patients and is at least as effective as conventional parenteral neuroleptic therapy, has been analyzed at the acute ward of Psychiatric Clinic, Clinical hospital Split. Methods: This was a prospective, naturalistic study, comparing the efficacy, safety and tolerability of risperidone oral solution versus conventional neuroleptic haloperidol in treatment of acute and agitated psychotic patients. The subjects were 60 patients admitted at Acute Ward of Psychiatry Clinic of Clinical Hospital Split in Split, Croatia, who required emergency medication for the control of agitation and/or violence. Inclusion criteria included men or women 18 years old and older ; ICD X diagnosis of acute exacerbation of schizophrenia or schizoaffective disorder, mania with psychotic features, acute paranoid reaction, or delusional disorders ; a score of  14 on a 5- item acute agitation cluster derived from the Positive and negative Syndrome Scale (PANSS) ; and a score  3 on the Clinical Global Impressions-Severity of Illness scale (CGI-S). Exclusion criteria included delirium, epilepsy, or mental retardation ; intoxication or symptoms of withdrawal from alcohol or other psychoactive substances ; clinical laboratory values indicating serious medical illness ; treatment with any antipsychotic or benzodiazepine within 6 hours of screening ; a history of neuroleptic malignant syndrome or known hypersensitivity to an of the trial medications ; treatment with a depot antipsychotic within 1 treatment cycle of screening ; and use of disallowed medication. Efficacy was assessed with the Positive and Negative Syndrome Scale (PANSS), 13-item acute- agitation cluster, Clinical Global Impressions (CGI) Scale and Behavioural Activity Rating Scale (BARS), side effects were also assessed. Summary of the results: Statistically significant difference between the two groups was evident in the group of patients treated with risperidone oral solution during the 24 hours (mean 53.67, p = 0.002187) and 3 months (mean 23.67 p = 0.004291) compared to the patients treated with haloperidol. Statistically significant difference in the CGI scale in the group of patients treated with risperidone oral solution was evident after 24 hours of treatment (mean 5.10, p = 0.002616). Also statistically significant difference between the two groups in the BARS Scale was evident in the group of patients treated with risperidone oral solution after 24 hours (mean 5.10, p = 0.000436) and 3 days (mean 4.57, p = 0.020422) of the treatment. Conclusion: Fast remission or suppression of positive symptoms, as well as of agitation, hostility, excitement, and aggressiveness, is a primary goal in the treatment of acute schizophrenic exacerbations. Conventional approach to acute psychotic patients was accustomed to parenteral therapy with incisive neuroleptics. The oral solution of atypical antipsychotic risperidone is new, effective therapeutic possibility in acute conditions of the patients, who because of the acute psychotic state, very often refuse to take medication. The oral solution offered as a beverage rarely spares a patient and medical staff of unpleasant parenteral administration of a medicine.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA